McMaster researcher: peptide hype is outrunning the evidence

Stuart Phillips, Tier 1 Canada Research Chair in Skeletal Muscle Health and Kinesiology Professor at McMaster University, published a piece in The Conversation arguing that the current peptide-therapy boom is built on far thinner evidence than the marketing suggests. The piece uses BPC-157 as its case study — citing the gap between hundreds of preclinical papers and a near-total absence of well-powered human trials — and applies the same critique to CJC-1295, ipamorelin, TB-500, and other compounds increasingly common in wellness clinics and biohacker forums. The piece adds to a growing line of mainstream-academic pushback against the peptide-therapy narrative that's traveled from research-chemical forums into mainstream wellness over the past three years.

What happened

Phillips's analysis, published May 6, 2026, makes a few specific quantitative arguments:

• Of 544 BPC-157 papers screened in a systematic review approach, only one involved humans in a musculoskeletal context
• Of 36 included studies, 35 used rodents or cells, with the remainder being small uncontrolled human work
• The available human evidence cited for BPC-157 includes a 16-patient knee pain retrospective study, a 12-woman interstitial cystitis pilot, and a 2-person intravenous safety pilot — none of which constitute the kind of randomized blinded data needed to establish efficacy
• The "translational squeeze" — the gap between rodent positive findings and approved human use — runs at greater than 20-to-1 failure rates across pharmacology broadly

The argument extends beyond BPC-157. Phillips notes that CJC-1295, ipamorelin, TB-500, and related compounds share the same evidence shape: plausible mechanisms, animal data, and very limited human work. He explicitly contrasts these with tesamorelin (FDA-approved for HIV-associated lipodystrophy) and semaglutide (multiple large trials), which have the level of evidence the speculative peptides lack.

The piece's core claim isn't that peptides don't work. It's that current evidence cannot distinguish actual peptide effects from placebo, natural recovery, and regression to the mean — and that properly blinded, placebo-controlled trials remain absent for almost all of the popular wellness-market peptides.

Why it matters

Phillips is a credible voice. McMaster's Kinesiology department is one of the most-cited muscle physiology programs in the world, and Phillips's own work on protein synthesis, resistance training, and muscle adaptation is widely cited in both academic and athlete communities. When a researcher of that profile publishes a peptide-skepticism piece in The Conversation — an academic-authored outlet read broadly outside academia — the framing reaches a different audience than the typical paper-in-journal critique.

The piece also lands at a notable moment. The FDA recently moved 12 peptides (including BPC-157, TB-500, KPV, MOTS-c, and others) from the Category 2 "do not compound" designation back toward potential 503A compounding eligibility, with a July 23-24 Pharmacy Compounding Advisory Committee meeting scheduled to evaluate seven of them. The Phillips piece arrives as the regulatory tide is moving toward more access, exactly when independent voices arguing for caution and better evidence become most important. See FDA sets July PCAC review for 7 compounded peptides for that regulatory context.

The piece also echoes themes the site has covered: the Croatian BPC-157 problem (single-source evidence), the AJSM Mayfield et al. injectable peptide primer (the academic field starting to weigh in), and Plastic surgeon pushes back on TikTok BPC-157 nose-slimming trend (clinicians flagging specific claims). The pattern is consistent: independent researchers and clinicians are increasingly publicly skeptical of the strength-peptide marketing case.

What to watch

A few things this piece sets up:

• More academic-voice critiques. Phillips's piece is unlikely to be the last. Expect more reviews and commentaries from independent researchers as peptide use grows and the FDA process unfolds.
• Industry response. The Sikiric Croatian research group has historically responded vigorously to critique (see the Józwiak et al. 2025 Pharmaceuticals exchange). Whether the Phillips piece draws a direct response from the research community most invested in BPC-157 is worth watching.
• PCAC submissions. The July 23-24 FDA Pharmacy Compounding Advisory Committee meeting on peptide 503A status will produce a docket record. The quality of evidence cited by both proponents and skeptics in that record is the more consequential venue than op-eds.
• Consumer behavior. Whether mainstream skepticism affects consumer demand for peptides remains to be seen. The GLP-1 wellness market grew through years of mainstream-skepticism articles; the strength-peptide market may follow the same pattern.

Sources

• The peptide problem: Hype is outrunning the evidence — The Conversation, May 6, 2026, by Stuart Phillips
• Stuart Phillips faculty profile — McMaster University Kinesiology